期刊文献+

芬太尼透皮贴剂用于30例难治性PHN的疗效及不良反应

The efficacy and side effect of fentanyl transdermal system in the treatment of intractable postherpetic neuralgia in 30 cases
暂未订购
导出
摘要 目的观察芬太尼透皮贴剂对难治性带状疱疹后遗神经痛的疗效及不良反应。方法将带状疱疹后遗神经痛患者30例(常规药物联合神经阻滞治疗1个疗程后VAS>5分)分为曲马多组(T组)、芬太尼组(F组),每组15例。结果两组治疗后VAS评分均降低(P<0.05),F组更为显著(P<0.05)。治疗后两组生活质量评分均明显升高(P<0.05),F组较高(P<0.05)。F组恶心、呕吐发生率较T组低(P>0.05);F组未出现排尿困难,T组发生率为26.67%(P<0.05);T组在治疗后便秘发生率为40%,F组无便秘情况(P<0.05);F组嗜睡的发生率比T组高(P<0.05);两组均未发生呼吸抑制。结论芬太尼透皮贴剂用于难治性带状疱疹后遗神经痛镇痛效果好,不良反应较少。 Objective To evaluate the effects of fentanyl transdermal system on intractable postherpetic neuralgia .Methods 30 patients(after 1 course of conventional drugs with nerve block therapy ,VAS score〉5 points)were randomly divided into tramadol group(group T ) and fentanyl group(group F) ,15 cases in each group .Results VAS of the two groups decreased after treatment (P〈0 .05) ,group F decreased more significantly(P〈0 .05) .The quality of life scores after treatment in two groups were signifi-cantly increased(P〈0 .05) ,group F scoring was higher(P〈0 .05) .The incidence of side reaction ,nausea and vomiting was lower in group F(P〉0 .05) .The incidence of dysuria was 26 .67% in group T ,and there was no dysuria in group F(P〈0 .05) .Constipation of group T was 40% after treatment(P〈0 .05) .The incidence of somnolence of group F was higher than T group(P〈0 .05) .The two groups were no respiratory depression .Conclusion Fentanyl transdermal system for intractable postherpetic neuralgia has good analgesic effect ,less side effect ,and well-tolerated .
出处 《重庆医学》 CAS CSCD 北大核心 2013年第33期4026-4027,共2页 Chongqing medicine
关键词 疱疹 带状 神经痛 芬太尼 镇痛 不良反应 herpes zoster neuralgia fentanyl analgesia side effect
  • 相关文献

参考文献14

  • 1Beal B, Moeller-Bertram T, Schilling JM, et al. Gabapentin for once-daily treatment of post-herpetic neuralgia: a re- view[J]. Clin Interv Aging,2012,7(3) :249-255.
  • 2Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia EJ ]. BMJ, 2003, 326 ( 7392 ) : 748-750.
  • 3Argoff CE. Review of current guidelines on the care of postherpetic neuralgia[J]. Postgrad Med, 2011,123 (5) .. 134-142.
  • 4Baron R. Neuropathic pain. the long path from mecha- nisms to mechanism-based treatment [J]. Anaesthesist, 2000,49 (5) : 373-386.
  • 5Srinivas nalamachuand patricia morley-forster. Diagnosing and managing postherpetic neuralgia [J], Drugs Aging, 2012,29(11) ..863-869.
  • 6Watson CP. The treatment of neuropathic pain: antide- pressants and opioids[J]. Clin J Pain,2000,16(2) :49-55.
  • 7Attal N. Neuropathic pain: mechanisms, therapeutic ap- proach,and interpretation of clinical trials[J]. Continu- um,2012,18(1) 161-175.
  • 8Watson CP. Herpes zoster and postherpetic neuralgia[J]. 2MAJ,2010,182(16) :1713-1714.
  • 9Jensen TS, Gottrup H, Sindrup SH, et al. The clinical pic- ture of neuropathic pain[J]. Eur J Pharmacol, 2001,429 (1) : 1-11.
  • 10Argoff CE. Review of current guidelines on the care of postherpetic neuralgia[J]. Postgrad Med, 2011,123 (5) : 134-142.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部